TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:20
GH Research PLC ( GHRS ) https://www.ghres.com
11.09USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
GHRS
48.06%
SPY
32.74%
GHRS
0.00%
SPY
92.93%
GHRS
0.00%
SPY
224.41%
GHRS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
576.91
502.07
0.17
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-13.64
0.00
2.56
-6.18
0.00
-12.99
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-19.39
-16.33
0.00
Other Earnings and Cash Flow Stats:
GH Research PLC ( GHRS ) Net Income TTM ($MM) is -28.83
GH Research PLC ( GHRS ) Operating Income TTM ($MM) is -35.94
GH Research PLC ( GHRS ) Owners' Earnings Annual ($MM) is 0.00
GH Research PLC ( GHRS ) Current Price to Owners' Earnings ratio is 0.00
GH Research PLC ( GHRS ) EBITDA TTM ($MM) is -34.04
GH Research PLC ( GHRS ) EBITDA Margin is 0.00%
Capital Allocation:
GH Research PLC ( GHRS ) has paid 0.00 dividends per share and bought back -0.039367999999996 million shares in the past 12 months
GH Research PLC ( GHRS ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
GH Research PLC ( GHRS ) Interest-bearing Debt ($MM) as of last quarter is 0
GH Research PLC ( GHRS ) Annual Working Capital Investments ($MM) are 2
GH Research PLC ( GHRS ) Book Value ($MM) as of last quarter is 225
GH Research PLC ( GHRS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
GH Research PLC ( GHRS ) has 86 million in cash on hand as of last quarter
GH Research PLC ( GHRS ) has 6 million of liabilities due within 12 months, and long term debt 0 as of last quarter
GH Research PLC ( GHRS ) has 52 common shares outstanding as of last quarter
GH Research PLC ( GHRS ) has 0 million USD of preferred stock value
Academic Scores:
GH Research PLC ( GHRS ) Altman Z-Score is 50.85 as of last quarter
GH Research PLC ( GHRS ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
GH Research PLC ( GHRS ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of GH Research PLC ( GHRS ) for the amount of $ on
40.39% of GH Research PLC ( GHRS ) is held by insiders, and 56.74% is held by institutions
GH Research PLC ( GHRS ) went public on 2021-06-25
Other GH Research PLC ( GHRS ) financial metrics:
FCF:-32.20
Unlevered Free Cash Flow:-42.27
EPS:-0.43
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-10.01
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About GH Research PLC ( GHRS ) :
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.